Advertisement

Pharmacy World and Science

, Volume 27, Issue 3, pp 202–207 | Cite as

Implementation of a Pharmacist-Led Clinic for Hypertensive Patients in Primary Care – A Pilot Study

  • Fiona ReidEmail author
  • Pat Murray
  • Marion Storrie
Article

Abstract

Objectives:To implement a pharmacist-led Hypertension Management Clinic in one general medical practice. To evaluate the impact of the clinic on blood pressure (BP) control and prevention of coronary heart disease (CHD). Method:A total of 242 patients attended the pharmacist-led hypertension clinic over a 10-month period. Lifestyle and drug therapy alterations were implemented to achieve British Hypertension Society (BHS) target level BP. A sub-group of 160 patients were used to compare BP control in the clinic setting against that with the general practitioner (GP). Assessment was made of 10-year CHD risk in patients with no artherosclerotic disease. Patients with underlying artherosclerotic disease were prescribed statins, and antiplatelet drugs where indicated. Main outcome measures:Changes in numbers of hypertensive patients meeting the BHS target level BP. Changes in prescribing of antiplatelet agents and statins for primary and secondary prevention of artherosclerosis. Results:In 206 patients with established hypertension, the number achieving target level BPs increased from 74 (36%) pre-clinic to 174 (85%) post-clinic; P < 0.001 chi-squared test. After attending the clinic, for 5 months 74 patients (80%) achieved target level BP in the clinic compared with 27 (40%) with standard GP care; P < 0.001 chi-squared test. Of 188 patients assessed for primary prevention therapy, 126 (67%) required treatment with aspirin and 37 (20%) with a statin. Post-clinic 101 (80%) received aspirin compared with 17 (13%) pre-clinic and 34 (92%) received a statin in comparison with 4 (11%) pre-clinic; both P < 0.001 chi-squared test.A total of 52 (96%) of 54 patients received an antiplatelet agent for secondary prevention of artherosclerosis compared with 40 patients (74%) pre-clinic. Thirty six of 54 patients required a statin for secondary prevention. Thirty five patients (97%) received a statin compared with 23 (64%) pre-clinic; both P < 0.01 chi-squared test. Conclusion:Implementation of a pharmacist-led clinic improved blood pressure control and appropriate prescribing of antiplatelet agents and statins for primary prevention of CHD and secondary prevention of artherosclerosis.

Keywords

Antihypertensive agent Hypertension clinic Ischaemic heart disease Pharmaceutical care Practice guideline Primary medical care Primary prevention Scotland Secondary prevention 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ramsay, Le, Williams, B, Johnston, DG,  et al. 1999Guidelines for the management of hypertension: report of the third working party of the British Hypertension SocietyJ Hum Hypertens1356992CrossRefPubMedGoogle Scholar
  2. 2.
    Wood, D, Durrington, P, Poulter, N,  et al. 1998Joint British recommendations on prevention of coronary heart disease in clinical practiceHeart(Suppl)2S15Google Scholar
  3. 3.
    Robson, J, Boomla, K, Hart, B, Feder, G. 2000Estimating cardiovascular risk for primary prevention: outstanding questions for primary careBr Med J3207024Google Scholar
  4. 4.
    Eisenberg, J. 2000Guidelines do not consider workload implications in primary careBMJ320576CrossRefGoogle Scholar
  5. 5.
    Marshall, T, Rouse, A. 2000Guidelines have serious weaknessesBMJ320576CrossRefGoogle Scholar
  6. 6.
    New GMS contract 2003 – Investing in general practice. London :BMJ Publications, 2003Google Scholar
  7. 7.
    The Life Study Group2002Cardiovascular morbidity and mortality In The Losartan Intervention For Endpoint reduction in hypertension study (LIFE)Lancet3599951003Google Scholar
  8. 8.
    The ALLHAT Officers and Coordinatorsforthe ALLHAT Collaborative Research Group2002Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)J Am Med Assoc288298197Google Scholar
  9. 9.
    Scottish Intercollegiate Guidelines Network (SIGN) Hypertension in Older People. Edinburgh: SIGN; 2001 (SIGN Publication no. 49).Google Scholar
  10. 10.
    The Tone Collaborative Research Group.1998Sodium reduction and weight loss in the treatment of hypertension in older persons A randomized controlled Trial of Nonpharmacologic Interventions in the ElderlyJ Am Med Assoc27983946Google Scholar
  11. 11.
    Xin, X, He, J, Frontini, MG, Ogden, LG, Motsamai, OI, Whelton, PK. 2001Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trialsHypertension3811127PubMedGoogle Scholar
  12. 12.
    Brand MB, Mulcrow CD, Chiquette E et al. Dieting to control body weight for controlling hypertension in adults. The Cochrane Library Issue 3, 1999.Google Scholar
  13. 13.
    UK Prospective diabetes study group1998Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ31770313Google Scholar
  14. 14.
    Coca, A. 1998Actual blood pressure control: are we doing things right?J Hypertens16S4551CrossRefGoogle Scholar
  15. 15.
    Ruilope, LM. 1995The hidden truth: what do the clinical trials really tell us about BP control?J Hum Hypertens9S3S7Google Scholar
  16. 16.
    UK Prospective diabetes study group1998Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ31770313Google Scholar
  17. 17.
    Messereli, F, Mittler, BS. 1998Framingham at 50Lancet3521006CrossRefPubMedGoogle Scholar
  18. 18.
    Wallis, EJ, Ramsay, LE, Haq, UI,  et al. 2000Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey populationBMJ320671676CrossRefPubMedGoogle Scholar
  19. 19.
    Jackson, R. 2000Updated New Zealand cardiovascular disease risk benefit prediction guideBMJ32070910CrossRefPubMedGoogle Scholar
  20. 20.
    Erickson, SR, Slaughter, R, Halapy, H. 1997Pharmacists ability to influence outcomes of hypertension therapyPharmacotherapy171407PubMedGoogle Scholar
  21. 21.
    Carter, BL, Barnette, DJ, Chrischilles, E, Mazzotti, GJ, Asali, ZJ. 1997Evaluation of hypertensive patients after care provided by community pharmacists in a rural settingPharmacotherapy17127485PubMedGoogle Scholar
  22. 22.
    Bogden, PE, Abbott, RD, Williamson, P, Onopa, JK, Koontz, LM. 1998Comparing standard care with a physician and pharmacist team approach for in controlled hypertensionJ Gen Intern Med137405CrossRefPubMedGoogle Scholar
  23. 23.
    Okamoto, MP, Nakahiro, RK. 2001Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinicPharmacotherapy20133744CrossRefGoogle Scholar
  24. 24.
    Scottish Executive. Our National Health: A plan for action, a plan for change. Edinburgh 2000.Google Scholar
  25. 25.
    Jones, AF, Walker, J, Jewkes, C,  et al. 2001Comparative accuracy of cardiovascular risk prediction methods in primary care patientsHeart853743CrossRefPubMedGoogle Scholar
  26. 26.
    Isles, CG, Ritchie, LD, Murchie, P, Norrie J., Risk 2000Assessment of primary prevention of coronary heart disease: randomised comparison of three scoring methodsBMJ3206901CrossRefPubMedGoogle Scholar
  27. 27.
    McManus, RJ, Mant, J, Meulendijks, M,  et al. 2002Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional studyBMJ32445964CrossRefPubMedGoogle Scholar
  28. 28.
    Hepler, CD, Strand, LM. 1990Opportunities and responsibilities in pharmaceutical careAm J Hosp Pharm4753343PubMedGoogle Scholar
  29. 29.
    MLX 2842002Proposals for supplementary prescribing by nurses and pharmacists and proposed amendments to the prescription only medicines (human use) order 1997Medicines Control AgencyLondonGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  1. 1.Pharmacy DepartmentLothian Primary Care Trust, Edinburgh, Newbyres Medical Group Midlothian and Lothian Pharmacy Academic Practice UnitGorebridgeUK
  2. 2.Pharmacy DepartmentLothian Primary Care Trust, Edinburgh, and Lothian Pharmacy Academic Practice UnitUK
  3. 3.Midlothian Health Care Cooperative and Newbyres Medical GroupGorebridgeUK

Personalised recommendations